 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.
Doctors often avoid ß-blockers in patients with lung diseases such as asthma. They worry that the drugs will narrow airways and cause severe asthma attacks or sudden shortness of breath. Unfortunately, many patients have both lung disease and a condition that can be treated with ß-blockers. In theory, the ß-1–blockers that act mainly on the heart may be "safe" for these patients. But what does research evidence show?
SUMMARIES FOR PATIENTS
Are Beta-1–Blockers Safe for Patients with Lung Disease?
5 November 2002 | Volume 137 Issue 9 | Page I-31
Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians-American Society of Internal Medicine.
The summary below is from the full report titled "Cardioselective ß-Blockers in Patients with Reactive Airway Disease: A Meta-Analysis." It is in the 5 November 2002 issue of Annals of Internal Medicine (volume 137, pages 715-725). The authors are SR Salpeter, TM Ormiston, and EE Salpeter.
What is the problem and what is known about it so far?
Doctors use ß-blocker drugs to treat many conditions, including high blood pressure, chest pain (angina), heart attacks, and migraine headaches. There are several types of ß-blockers. Cardioselective ß-blockers (ß-1–blockers) act mainly on the heart. They slow heart rate, decrease blood pressure, and reduce the heart's workload. Other ß-blockers act on the heart but also may narrow blood vessels throughout the body and the airways to the lungs (bronchi).
Why did the researchers do this particular study?
The researchers wanted to see whether ß-1–blockers worsen lung function and symptoms in patients with airway disease.
Who was studied?
381 adults with reactive airway disease (asthma) who had participated in 1 of 29 different studies.
How was the study done?
Rather than doing a new study, the researchers summarized information from previous randomized trials. They looked at trials that compared ß-1–blockers with dummy (placebo) drugs in patients with mild to moderate reactive airway disease. They checked the following outcomes from these trials: symptoms of lung disease, use of inhaled asthma drugs, and the maximum amount of air that patients could exhale in 1 second (a measure called FEV1) before and after taking a ß-1–blocker.
What did the researchers find?
19 trials assessed outcomes after one dose of a ß-1–blocker. Compared with placebo, the ß-1–blockers decreased FEV1 only a small amount and did not increase symptoms. In 10 trials, ß-1–blockers were given for 3 days to 4 weeks. Compared with placebo, the ß-1–blockers did not increase symptoms or inhaler use and did not worsen FEV1.
What were the limitations of the study?
In the reviewed trials, patients took ß-1–blockers only for short periods (1 day to 4 weeks). None of the trials included patients with severe airway disease.
What are the implications of the study?
Beta-1–blockers do not significantly worsen lung function or symptoms in patients with mild to moderate reactive airway disease. They should not be withheld from patients with reactive airway disease who would otherwise benefit from them.
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  Y. R. B. M. van Gestel, S. E. Hoeks, D. D. Sin, G. M. J. M. Welten, O. Schouten, H. J. Witteveen, C. Simsek, H. Stam, F. W. Mertens, J. J. Bax, et al. Impact of Cardioselective {beta}-Blockers on Mortality in Patients with Chronic Obstructive Pulmonary Disease and Atherosclerosis Am. J. Respir. Crit. Care Med., October 1, 2008; 178(7): 695 - 700. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Falk, S. Kadiev, G. J. Criner, S. M. Scharf, O. A. Minai, and P. Diaz Cardiac Disease in Chronic Obstructive Pulmonary Disease Proceedings of the ATS, May 1, 2008; 5(4): 543 - 548. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Ling, W. Saleem, and C. D. Shee Concomitant use of {beta}-blockers and {beta}2-agonists Eur. Respir. J., April 1, 2008; 31(4): 905 - 906. [Full Text] [PDF]
|
|
|
|
 |
|
 D. H Au Use of {beta} blockers in patients with COPD Thorax, April 1, 2008; 63(4): 296 - 298. [Full Text] [PDF]
|
|
|
|
 |
|
 D. M Shavelle Long term medical treatment of stable coronary disease Heart, November 1, 2007; 93(11): 1473 - 1477. [Full Text] [PDF]
|
|
|
|
|
|
C. C Lang and D. M Mancini Non-cardiac comorbidities in chronic heart failure Heart, June 1, 2007; 93(6): 665 - 671. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. K. Pannu, W. Alvarez Jr., and E. K. Fishman {beta}-Blockers for Cardiac CT: A Primer for the Radiologist Am. J. Roentgenol., June 1, 2006; 186(6_Supplement_2): S341 - S345. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Auerbach and L. Goldman Assessing and Reducing the Cardiac Risk of Noncardiac Surgery Circulation, March 14, 2006; 113(10): 1361 - 1376. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Andreas, S. D. Anker, P. D. Scanlon, and V. K. Somers Neurohumoral Activation as a Link to Systemic Manifestations of Chronic Lung Disease Chest, November 1, 2005; 128(5): 3618 - 3624. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Redelmeier, D. Scales, and A. Kopp {beta} blockers for elective surgery in elderly patients: population based, retrospective cohort study BMJ, October 22, 2005; 331(7522): 932. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Egred, S. Shaw, B. Mohammad, P. Waitt, and E. Rodrigues Under-use of beta-blockers in patients with ischaemic heart disease and concomitant chronic obstructive pulmonary disease QJM, July 1, 2005; 98(7): 493 - 497. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. J. van der Woude, J. Zaagsma, D. S. Postma, T. H. Winter, M. van Hulst, and R. Aalbers Detrimental Effects of {beta}-Blockers in COPD: A Concern for Nonselective {beta}-Blockers Chest, March 1, 2005; 127(3): 818 - 824. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. I Lindblad, M. B Artz, C. F Pieper, R. J Sloane, E. R Hajjar, C. M Ruby, K. E Schmader, and J. T Hanlon Potential Drug-Disease Interactions in Frail, Hospitalized Elderly Veterans Ann. Pharmacother., March 1, 2005; 39(3): 412 - 417. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Zaugg, C. Schulz, J. Wacker, and M. C. Schaub Sympatho-modulatory therapies in perioperative medicine Br. J. Anaesth., July 1, 2004; 93(1): 53 - 62. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. R. Salpeter, T. M. Ormiston, and E. E. Salpeter Cardiovascular Effects of {beta}-Agonists in Patients With Asthma and COPD: A Meta-Analysis Chest, June 1, 2004; 125(6): 2309 - 2321. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. R. Salpeter, T. M. Ormiston, and E. E. Salpeter Meta-Analysis: Respiratory Tolerance to Regular {beta}2-Agonist Use in Patients with Asthma Ann Intern Med, May 18, 2004; 140(10): 802 - 813. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Callaerts-Vegh, K. L. J. Evans, N. Dudekula, D. Cuba, B. J. Knoll, P. F. K. Callaerts, H. Giles, F. R. Shardonofsky, and R. A. Bond Effects of acute and chronic administration of {beta}-adrenoceptor ligands on airway function in a murine model of asthma PNAS, April 6, 2004; 101(14): 4948 - 4953. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. D. Auerbach and J. Kleinbart Update in Hospital Medicine Ann Intern Med, March 2, 2004; 140(5): 363 - 369. [Full Text] [PDF]
|
|
|
|
 |
|
 J F Kirwan, J A Nightingale, C Bunce, and R Wormald Do selective topical {beta} antagonists for glaucoma have respiratory side effects? Br. J. Ophthalmol., February 1, 2004; 88(2): 196 - 198. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R Andrus, K. P Holloway, and D. B Clark Use of {beta}-Blockers in Patients with COPD Ann. Pharmacother., January 1, 2004; 38(1): 142 - 145. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Porat, K. Berend, and P. August Initial Treatment of Hypertension N. Engl. J. Med., September 11, 2003; 349(11): 1090 - 1091. [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Brotman and S. D. Frost The JNC 7 Hypertension Guidelines JAMA, September 10, 2003; 290(10): 1313 - 1314. [Full Text] [PDF]
|
|
|
|
|
|
D. J. Shulan, M. Katlan, and M. Lavsky-Shulan Use of {beta}-Blockers in Patients with Reactive Airway Disease Ann Intern Med, August 19, 2003; 139(4): 304 - 304. [Full Text] [PDF]
|
|
|
|
 |
|
 J B. Jura and A. R Blanchard Review: cardioselective {beta}1 blockers given for 3 days to 4 weeks do not reduce respiratory function in reactive airway disease Evid. Based Med., May 1, 2003; 8(3): 73 - 73. [Full Text] [PDF]
|
|
|
|
|
|
I. Malik JournalScan Heart, February 1, 2003; 89(2): 239 - 240. [Full Text] [PDF]
|
|
|
|
|
|
E Gamble Cardioselective {beta} blockers do not cause adverse respiratory effects in mild to moderate reactive airway disease Thorax, February 1, 2003; 58(2): 142 - 142. [Full Text]
|
|
|
|
 |
|
 Cardioselective {beta}-Blockers in Patients with Reactive Airways Journal Watch (General), November 26, 2002; 2002(1126): 3 - 3. [Full Text]
|
|
|
|
|
|
P. E. Epstein Fresh Air and {beta}-Blockade Ann Intern Med, November 5, 2002; 137(9): 766 - 767. [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Article
